Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;67(2):182-6.
doi: 10.1053/j.ajkd.2015.07.035. Epub 2015 Oct 23.

Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders

Affiliations
Review

Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders

Richard A Sherman. Am J Kidney Dis. 2016 Feb.

Abstract

Hyperphosphatemia in dialysis patients is routinely attributed to nonadherence to diet, prescribed phosphate binders, or both. The role of individual patient variability in other determinants of phosphate control is not widely recognized. In a manner that cannot be explained by dialysis parameters or serum phosphate levels, dialytic removal of phosphate may vary by >400mg per treatment. Similarly, enteral phosphate absorption, unexplained by diet or vitamin D intake, may differ by ≥250mg/d among patients. Binder efficacy also varies among patients, with 2-fold differences reported. One or more elements of this triple threat-varying dialytic removal, phosphate absorption, and phosphate binding-may account for hyperphosphatemia in dialysis patients rather than nonadherence to therapy. Just as the cause(s) of hyperphosphatemia may vary, so too may an individual patient's response to different therapeutic interventions.

Keywords: Hyperphosphatemia; binder efficacy; dialysis; dialytic phosphate removal; dietary phosphate; enteral phosphate absorption; individual variation; phosphate binders; phosphate levels; treatment adherence; vitamin D.

PubMed Disclaimer

MeSH terms

LinkOut - more resources